The role of Plk3 in oncogenesis

Oncogene

Volumn 35, Issue 2, 2016, Pages 135-147

  Helmke, C ^a   Becker, S ^a   Strebhardt, K ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; POLO LIKE KINASE 3; PROTEIN INHIBITOR; CELL CYCLE PROTEIN; ONCOPROTEIN; PLK3 PROTEIN, HUMAN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE; VOLASERTIB;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL STRESS; CELLULAR STRESS SIGNAL; DNA DAMAGE; DNA REPLICATION; ENDOPLASMIC RETICULUM STRESS; GENOTOXICITY; HUMAN; HYPEROSMOTIC STRESS; HYPOXIA; MITOSIS; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROTEIN TERTIARY STRUCTURE;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CELL CYCLE PROTEINS; DNA DAMAGE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES;

EID: 84954382715     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.105     Document Type: Review

References (144)

1. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8: 473-480.
2. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001; 7: 548-552.
3. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
4. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
5. Sunkel CE, Glover DM. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci 1988; 89: 25-38.
6. Llamazares S, Moreira A, Tavares A, Girdham C, Spruce BA, Gonzalez C et al. polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev 1991; 5: 2153-2165.
7. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10: 265-275.
8. Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M. Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol 2014; 15: 433-452.
9. de Carcer G, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 2011; 10: 2255-2262.
10. Petronczki M, Lenart P, Peters JM. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev Cell 2008; 14: 646-659.
11. van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle 2006; 5: 853-864.
12. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5: 429-440.
13. Craig SN, Wyatt MD, McInnes C. Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov 2014; 9: 773-789.
14. Gjertsen BT, Schoffski P. Discovery and development of the polo-like kinase inhibitor volasertib in cancer therapy. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund: UK, 2014.
15. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330.
16. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nature reviews Drug discovery 2010; 9: 643-660.
17. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794.
18. Cholewa BD, Liu X, Ahmad N. The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cancer Res 2013; 73: 6848-6855.
19. McInnes C, Wyatt MD. PLK1 as an oncology target: current status and future potential. Drug Discov Today 2011; 16: 619-625.
20. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24: 267-276.
21. Berg T, Bug G, Ottmann OG, Strebhardt K. Polo-like kinases in AML. Expert Opin Investig Drugs 2012; 21: 1069-1074.
22. Dohner H, Lubbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM et al. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 2014; 124: 1426-1433.
23. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15: 3094-3102.
24. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322.
25. Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D et al. NMS-P937, an orally available, specific, small molecule polo-like kinase 1 inhibitor with antitumor activity in solid and haematological malignancies. Mol Cancer Ther 2012; 11: 1006-1016.
26. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009; 69: 6969-6977.
27. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994; 91: 1736-1740.
28. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 2794-2797.
29. Raab M, Pachl F, Kramer A, Kurunci-Csacsko E, Dotsch C, Knecht R et al. Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells. Cell Res 2014; 24: 1141-1145.
30. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29: 354-358.
31. Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA 2000; 283: 479-480.
32. Donohue PJ, Alberts GF, Guo Y, Winkles JA. Identification by targeted differential display of an immediate early gene encoding a putative serine/threonine kinase. J Biol Chem 1995; 270: 10351-10357.
33. Kauselmann G, Weiler M, Wulff P, Jessberger S, Konietzko U, Scafidi J et al. The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J 1999; 18: 5528-5539.
34. Bergeron M, Motter R, Tanaka P, Fauss D, Babcock M, Chiou SS et al. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 alpha-synuclein phosphorylation in mouse brain. Neuroscience 2014; 256: 72-82.
35. Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem 2009; 284: 2598-2602.
36. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M et al. Phosphorylation of synucleins by members of the polo-like kinase family. J Biol Chem 2010; 285: 2807-2822.
37. Zhou JX, Zhang HB, Huang Y, He Y, Zheng Y, Anderson JP et al. Tenuigenin attenuates alpha-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. CNS Neurosci Ther 2013; 19: 688-694.
38. Ouyang B, Pan H, Lu L, Li J, Stambrook P, Li B et al. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J Biol Chem 1997; 272: 28646-28651.
39. Li B, Ouyang B, Pan H, Reissmann PT, Slamon DJ, Arceci R et al. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J Biol Chem 1996; 271: 19402-19408.
40. Holtrich U, Wolf G, Yuan J, Bereiter-Hahn J, Karn T, Weiler M et al. Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages. Oncogene 2000; 19: 4832-4839.
41. Chase D, Feng Y, Hanshew B, Winkles JA, Longo DL, Ferris DK. Expression and phosphorylation of fibroblast-growth-factor-inducible kinase (Fnk) during cellcycle progression. Biochem J 1998; 333: 655-660.
42. Bahassi el M, Conn CW, Myer DL, Hennigan RF, McGowan CH, Sanchez Y et al. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 2002; 21: 6633-6640.
43. Zimmerman WC, Erikson RL. Polo-like kinase 3 is required for entry into S phase. Proc Natl Acad Sci USA 2007; 104: 1847-1852.
44. Wang Q, Xie S, Chen J, Fukasawa K, Naik U, Traganos F et al. Cell cycle arrest and apoptosis induced by human polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol Cell Biol 2002; 22: 3450-3459.
45. Ruan Q, Wang Q, Xie S, Fang Y, Darzynkiewicz Z, Guan K et al. Polo-like kinase 3 is Golgi localized and involved in regulating Golgi fragmentation during the cell cycle. Exp Cell Res 2004; 294: 51-59.
46. Zimmerman WC, Erikson RL. Finding Plk3. Cell Cycle 2007; 6: 1314-1318.
47. Conn CW, Hennigan RF, Dai W, Sanchez Y, Stambrook PJ. Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. Cancer Res 2000; 60: 6826-6831.
48. Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C et al. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem 2001; 276: 43305-43312.
49. Jiang N, Wang X, Jhanwar-Uniyal M, Darzynkiewicz Z, Dai W. Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis. J Biol Chem 2006; 281: 10577-10582.
50. Dai W, Li Y, Ouyang B, Pan H, Reissmann P, Li J et al. PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. Genes Chromosomes Cancer 2000; 27: 332-336.
51. Li MJ, Wang WW, Chen SW, Shen Q, Min R. Radiation dose effect of DNA repair-related gene expression in mouse white blood cells. Med Sci Monit 2011; 17: BR290-BR297.
52. Kis E, Szatmari T, Keszei M, Farkas R, Esik O, Lumniczky K et al. Microarray analysis of radiation response genes in primary human fibroblasts. Int J Radiat Oncol Biol Phys 2006; 66: 1506-1514.
53. Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M et al. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res 2005; 65: 10255-10264.
54. Zhou T, Chou JW, Simpson DA, Zhou Y, Mullen TE, Medeiros M et al. Profiles of global gene expression in ionizing-radiation-damaged human diploid fibroblasts reveal synchronization behind the G1 checkpoint in a G0-like state of quiescence. Environ Health Perspect 2006; 114: 553-559.
55. Jen KY, Cheung VG. Identification of novel p53 target genes in ionizing radiation response. Cancer Res 2005; 65: 7666-7673.
56. Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M et al. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem 2001; 276: 36194-36199.
57. Xie S, Wu H, Wang Q, Kunicki J, Thomas RO, Hollingsworth RE et al. Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2. Cell Cycle 2002; 1: 424-429.
58. Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M et al. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 2010; 51: 857-868.
59. Li Z, Niu J, Uwagawa T, Peng B, Chiao PJ. Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response. J Biol Chem 2005; 280: 16843-16850.
60. Lai WS, Parker JS, Grissom SF, Stumpo DJ, Blackshear PJ. Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts. Mol Cell Biol 2006; 26: 9196-9208.
61. Horner TJ, Lai WS, Stumpo DJ, Blackshear PJ. Stimulation of polo-like kinase 3 mRNA decay by tristetraprolin. Mol Cell Biol 2009; 29: 1999-2010.
62. Blackshear PJ. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem Soc Trans 2002; 30: 945-952.
63. Cheng KY, Lowe ED, Sinclair J, Nigg EA, Johnson LN. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J 2003; 22: 5757-5768.
64. Elia AE, Cantley LC, Yaffe MB. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 2003; 299: 1228-1231.
65. Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003; 115: 83-95.
66. Lee KS, Park JE, Kang YH, Zimmerman W, Soung NK, Seong YS et al. Mechanisms of mammalian polo-like kinase 1 (Plk1) localization: self- versus non-self-priming. Cell Cycle 2008; 7: 141-145.
67. Archambault V, D'Avino PP, Deery MJ, Lilley KS, Glover DM. Sequestration of polo kinase to microtubules by phosphopriming-independent binding to Map205 is relieved by phosphorylation at a CDK site in mitosis. Genes Dev 2008; 22: 2707-2720.
68. Alberts GF, Winkles JA. Murine FGF-inducible kinase is rapidly degraded via the nuclear ubiquitin-proteosome system when overexpressed in NIH 3T3 cells. Cell Cycle 2004; 3: 678-684.
69. Jang YJ, Lin CY, Ma S, Erikson RL. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci USA 2002; 99: 1984-1989.
70. Xu J, Shen C, Wang T, Quan J. Structural basis for the inhibition of polo-like kinase 1. Nat Struct Mol Biol 2013; 20: 1047-1053.
71. Bruinsma W, Macurek L, Freire R, Lindqvist A, Medema RH. Bora and Aurora-A continue to activate Plk1 in mitosis. J Cell Sci 2014; 127: 801-811.
72. van de Weerdt BC, van Vugt MA, Lindon C, Kauw JJ, Rozendaal MJ, Klompmaker R et al. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Mol Cell Biol 2005; 25: 2031-2044.
73. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008; 320: 1655-1658.
74. Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008; 455: 119-123.
75. Lee KS, Erikson RL. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol Cell Biol 1997; 17: 3408-3417.
76. Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang Y et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008; 68: 4077-4085.
77. De Franceschi L, Tomelleri C, Matte A, Brunati AM, Bovee-Geurts PH, Bertoldi M et al. Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. Blood 2011; 118: 5652-5663.
78. Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 2009; 81: 4493-4501.
79. Li H, Xing X, Ding G, Li Q, Wang C, Xie L et al. SysPTM: a systematic resource for proteomic research on post-translational modifications. Mol Cell Proteomics 2009; 8: 1839-1849.
80. Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and polo-like kinase activities in mitotic cells. Sci Signal 2011; 4: rs5.
81. Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 2012; 72: 2501-2511.
82. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
83. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482.
84. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-837.
85. Wang L, Gao J, Dai W, Lu L. Activation of polo-like kinase 3 by hypoxic stresses. J Biol Chem 2008; 283: 25928-25935.
86. Lu J, Wang L, Dai W, Lu L. Effect of hypoxic stress-activated polo-like kinase 3 on corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2010; 51: 5034-5040.
87. Wang L, Dai W, Lu L. Stress-induced c-Jun activation mediated by polo-like kinase 3 in corneal epithelial cells. J Biol Chem 2007; 282: 32121-32127.
88. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14: 359-370.
89. Salvi M, Trashi E, Cozza G, Franchin C, Arrigoni G, Pinna LA. Investigation on PLK2 and PLK3 substrate recognition. Biochim Biophys Acta 2012; 1824: 1366-1373.
90. Iida M, Matsuda M, Komatani H. Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1. Biochem J 2008; 411: 27-32.
91. Wang J, Beauchemin M, Bertrand R. Bcl-xL phosphorylation at Ser49 by polo kinase 3 during cell cycle progression and checkpoints. Cell Signal 2011; 23: 2030-2038.
92. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC et al. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008; 13: 36-47.
93. Bahassi el M, Hennigan RF, Myer DL, Stambrook PJ. Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation. Oncogene 2004; 23: 2658-2663.
94. Zhang H, Shi X, Paddon H, Hampong M, Dai W, Pelech S. B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1. J Biol Chem 2004; 279: 35726-35734.
95. Lopez-Sanchez I, Sanz-Garcia M, Lazo PA. Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation. Mol Cell Biol 2009; 29: 1189-1201.
96. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2012; 40: D261-D270.
97. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000; 2: 672-676.
98. Bahassi el M, Myer DL, McKenney RJ, Hennigan RF, Stambrook PJ. Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage. Mutat Res 2006; 596: 166-176.
99. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288: 1425-1429.
100. Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep 2000; 1: 71-79.
101. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001; 410: 842-847.
102. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8: 2540-2551.
103. Myer DL, Robbins SB, Yin M, Boivin GP, Liu Y, Greis KD et al. Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA damage but is not sufficient to produce tumors. Mutat Res 2011; 714: 1-10.
104. Myer DL, Bahassi el M, Stambrook PJ. The Plk3-Cdc25 circuit. Oncogene 2005; 24: 299-305.
105. Ouyang B, Li W, Pan H, Meadows J, Hoffmann I, Dai W. The physical association and phosphorylation of Cdc25C protein phosphatase by Prk. Oncogene 1999; 18: 6029-6036.
106. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-439.
107. Lopez-Girona A, Furnari B, Mondesert O, Russell P. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 1999; 397: 172-175.
108. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 240-246.
109. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-E136.
110. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-157.
111. Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev 1993; 7: 1309-1317.
112. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 1999; 13: 607-619.
113. Palmada M, Kanwal S, Rutkoski NJ, Gustafson-Brown C, Johnson RS, Wisdom R et al. c-jun is essential for sympathetic neuronal death induced by NGF withdrawal but not by p75 activation. J Cell Biology 2002; 158: 453-461.
114. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet 1999; 21: 326-329.
115. Sang M, Ando K, Okoshi R, Koida N, Li Y, Zhu Y et al. Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation. Genes Cells 2009; 14: 775-788.
116. Xu D, Yao Y, Jiang X, Lu L, Dai W. Regulation of PTEN stability and activity by Plk3. J Biol Chem 2010; 285: 39935-39942.
117. Han ES, Muller FL, Perez VI, Qi W, Liang H, Xi L et al. The in vivo gene expression signature of oxidative stress. Physiol Genomics 2008; 34: 112-126.
118. 2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-975.
119. Xu D, Yao Y, Lu L, Costa M, Dai W. Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha. J Biol Chem 2010; 285: 38944-38950.
120. Li Z, Li J, Bi P, Lu Y, Burcham G, Elzey BD et al. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol 2014; 34: 3642-3661.
121. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008; 27: 5527-5541.
122. Wang L, Dai W, Lu L. Hyperosmotic stress-induced corneal epithelial cell death through activation of polo-like kinase 3 and c-Jun. Invest Ophthalmol Vis Sci 2011; 52: 3200-3206.
123. Wang L, Payton R, Dai W, Lu L. Hyperosmotic stress-induced ATF-2 activation through polo-like kinase 3 in human corneal epithelial cells. J Biol Chem 2011; 286: 1951-1958.
124. Mamrosh JL, Lee JM, Wagner M, Stambrook PJ, Whitby RJ, Sifers RN et al. Nuclear receptor LRH-1/NR5A2 is required and targetable for liver endoplasmic reticulum stress resolution. eLife 2014; 3: e01694.
125. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94: 1863-1877.
126. Raab M, Kappel S, Kramer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun 2011; 2: 395.
127. Utada Y, Emi M, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G et al. Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer. Clin Cancer Res 2000; 6: 3193-3198.
128. Bieche I, Khodja A, Lidereau R. Deletion mapping in breast tumor cell lines points to two distinct tumor-suppressor genes in the 1p32-pter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma. Oncol Rep 1998; 5: 267-272.
129. Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y et al. Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 2002; 35: 170-175.
130. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90: 815-821.
131. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005; 446: 442-450.
132. Larsson E, Sander C, Marks D. mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol 2010; 6: 433.
133. McInnes C, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 2005; 5: 181-197.
134. McInnes C, Estes K, Baxter M, Yang Z, Farag DB, Johnston P et al. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther 2012; 11: 1683-1692.
135. Shan HM, Wang T, Quan JM. Crystal structure of the polo-box domain of polo-like kinase 2. Biochem Biophys Res Commun 2015; 456: 780-784.
136. Yuan J, Kramer A, Eckerdt F, Kaufmann M, Strebhardt K. Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res 2002; 62: 4186-4190.
137. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008; 15: 459-466.
138. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem 2009; 10: 1145-1148.
139. Yuan J, Sanhaji M, Kramer A, Reindl W, Hofmann M, Kreis NN et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 2011; 179: 2091-2099.
140. Srinivasrao G, Park JE, Kim S, Ahn M, Cheong C, Nam KY et al. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. PLoS One 2014; 9: e107432.
141. Qian WJ, Park JE, Lim D, Park SY, Lee KW, Yaffe MB et al. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs. Chem Biol 2013; 20: 1255-1264.
142. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005; 24: 260-266.
143. Qian YW, Erikson E, Maller JL. Mitotic effects of a constitutively active mutant of the Xenopus polo-like kinase Plx1. Mol Cell Biol 1999; 19: 8625-8632.
144. Ma S, Charron J, Erikson RL. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol 2003; 23: 6936-6943.